74.00GBp-6.33%Mkt Cap: 336.78M GBpP/E: —Last update: 2026-06-01
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate fo…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap336.78M GBp
Enterprise Value331.54M GBp
Revenue (TTM)113.00K GBp
Gross Profit113.00K GBp
Net Income (TTM)-37.06M GBp
Revenue/Share0.0000 GBp
Last Price74.00 GBp
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-21.03
PEG—
EV/EBITDA-11.52
EV/Revenue2933.99
P/S3181.74
P/B131.67
EPS (TTM)-0.09
EPS (Forward)-0.04
52W Range
0.000080% of range92.00
52W High92.00 GBp
52W Low0.0000 GBp
Profitability
Gross Margin100.00%
Oper. Margin-30075.44%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-630.42%
ROA-48.65%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.60M GBp
CapEx (TTM)339.00K GBp
FCF Margin-5188.94%
FCF Yield-1.74%
Net Debt850.00K GBp
Net Debt/EBITDA-0.03
Balance Sheet
Debt/Equity2.47
Current Ratio0.89
Quick Ratio0.89
Book Value/Sh0.0060 GBp
Cash/Share0.0400 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateJan 26, 2016
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)86.50 GBp
Target Range60.00 GBp – 103.00 GBp
# Analysts4
Ownership
Shares Out.455.11M
Float393.04M
Insiders1.22%
Institutions7.95%
Technical
SMA 5074.33 (-0.4%)
SMA 20066.37 (+11.5%)
Beta-0.10
S&P 52W Chg27.94%
Avg Vol (30d)2.24M
Avg Vol (10d)1.83M
Technical Indicators
RSI (14)51.3
MACD0.8233
MACD Signal2.0150
MACD Hist.-1.1917
BB Upper90.77 GBp
BB Middle80.43 GBp
BB Lower70.08 GBp
BB Width25.72%
ATR (14)9.149 GBp
Vol Ratio (20d)0.46x